We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00604019
Recruitment Status : Completed
First Posted : January 29, 2008
Results First Posted : December 7, 2012
Last Update Posted : March 4, 2013
Information provided by (Responsible Party):
Gourang P Patel, Rush University Medical Center

Brief Summary:
We are performing a prospective, randomized, controlled trial of dopamine versus norepinephrine for septic shock. The trial will enroll patients with suspected or documented site of infection and having 2 out of the three SIRS criteria. Patients will also be receiving standard of care, early-goal directed therapy including but not limited to fluid resuscitation, appropriate and early antibiotics, source control and evaluation for drotrecogin alpha where deemed appropriate, while being supported for septic shock.

Condition or disease Intervention/treatment Phase
Septic Shock Drug: Dopamine Drug: Norepinephrine Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 252 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
Study Start Date : March 2003
Primary Completion Date : August 2009
Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Dopamine
Patients that get Dopamine as an infusion for hypotension
Drug: Dopamine
Dopamine 5-20 mcg/kg/min to pre-determined max of 20
Active Comparator: Norepinephrine
Patients that get norepinephrine as an infusion for hypotension
Drug: Norepinephrine
Norepinephrine 5-20 mcg/min, to a pre-determined max of 20

Primary Outcome Measures :
  1. Efficacy [ Time Frame: 28 days ]
    Dead at 28 days

Secondary Outcome Measures :
  1. Safety, Arrythmia - Yes or no for Each Group [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients are transferred to our medical intensive care unit from the emergency room (ER), general medical floors, and from outside hospitals.
  • Patients were eligible if they were greater than 18 years of age
  • Presented with a diagnosis of SIRS plus a suspected or documented source of infection.

Exclusion Criteria:

  • Patients were not eligible if they were found to have hypovolemic and/or hemorrhagic etiologies of their vasodilatory shock or another etiology of their SIRS.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00604019

United States, Illinois
RUSH University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Study Chair: Robert A Balk, MD Rush University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gourang P Patel, Sub-PI, Rush University Medical Center
ClinicalTrials.gov Identifier: NCT00604019     History of Changes
Other Study ID Numbers: ORA-02102801
First Posted: January 29, 2008    Key Record Dates
Results First Posted: December 7, 2012
Last Update Posted: March 4, 2013
Last Verified: February 2013

Keywords provided by Gourang P Patel, Rush University Medical Center:
septic shock

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Dopamine Agents
Vasoconstrictor Agents
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents